One Drug for a Colon Still Flaring and a Knee That Just Started
Her joints and her gut are, for once, not in disagreement about what they need — they're in disagreement about what to avoid. The drug class best suited to one has direct trial evidence of harming the other.
Naomi R. finished culinary school eighteen months ago and is six months into her first line-cook job at a restaurant she genuinely loves — long enough to have stopped feeling provisional there, which is part of why the timing stung — when her Crohn's disease, diagnosed four years earlier and never fully quiet, flared into its worst stretch yet — a CDAI in the range her gastroenterologist calls moderately-to-severely active, with weight loss she can't afford to keep losing on a job that keeps her on her feet for ten-hour shifts. Three weeks into that flare, her right knee swelled hot and tender enough that standing at a line station became genuinely difficult, confirmed on exam and aspiration as an inflammatory, culture-negative peripheral arthritis — enteropathic arthritis, the joint disease that rides alongside inflammatory bowel disease closely enough that the two are often treated as one decision rather than two.
For once, her gut and her joint aren't asking for genuinely different things — they're both asking to avoid the same thing. If her joint disease alone were the question, IL-17 inhibition would be a reasonable, guideline-supported first reach for peripheral inflammatory arthritis. But IL-17A itself plays a real role in maintaining the gut's mucosal barrier, and the evidence against using it here is not theoretical: Hueber and colleagues randomized secukinumab against placebo in active Crohn's disease and stopped the trial early, having found the drug not merely ineffective but associated with worse outcomes than placebo — unexpected and clear enough to end the study. TNF monoclonal antibodies — not etanercept, which has no demonstrated efficacy for bowel disease at all — are established, effective therapy for both active Crohn's disease and the joint disease that travels with it, making this less a genuine tie between two good options than a case where one whole mechanism is simply off the table for her.
Her knee exam shows a large effusion with warmth and a positive bulge sign, and she's been favoring it enough over the past week that she's asked her manager for lighter station duty rather than a full shift off — she's reluctant, six months into a job she worked hard to get, to take more time away from the line than the flare is already costing her GI symptoms alone.
The one drug the joint literature would never pick on its own
I don't think this is actually a close call. The Hueber trial randomized secukinumab against placebo in active Crohn's disease and was stopped early because patients on the drug did worse than those on placebo — not a subtle signal, a trial-ending one. TNF monoclonal antibodies, by contrast, are established, effective therapy for moderate-to-severe Crohn's disease and for the joint disease that travels with it. Infliximab treats both problems she has right now with one drug.
I agree completely that IL-17 inhibition is off the table here, and I want to be clear I'm not reopening that. What I'd add before we finalize infliximab specifically: her flare is severe enough that we're talking about induction-intensity dosing, and we should confirm there's no active infection, no latent TB, and no heart failure history before committing to that particular TNF monoclonal antibody.
"A TNF monoclonal antibody" and "infliximab" aren't quite the same decision — adalimumab would serve the same dual purpose if anything infliximab-specific turns up on screening, and I'd rather name that alternative now than treat today's choice as having only one possible drug inside it.
Agreed on both points, and I'd add one thing about how we frame this for her: I wouldn't set up an expectation that her knee needs its own separate treatment track. Enteropathic arthritis activity commonly tracks with the underlying bowel disease — once her Crohn's flare is genuinely under control on an effective TNF monoclonal antibody, real improvement in the joint is the expected course, not a bonus outcome we're hoping for on top of the GI response.
Agreed: pre-biologic screening followed by infliximab induction, with both CDAI and knee examination tracked at the same follow-up intervals to confirm the expected parallel improvement.
Not agreed, though narrow: whether adalimumab should have been proposed as a genuinely equal first option rather than a contingency. The clinical pharmacologist would present both TNF monoclonal antibodies to her as an active choice from the start; the gastroenterologist, given her flare's severity, preferred to lead with infliximab's induction-dosing flexibility and hold adalimumab in reserve rather than present the decision as evenly split.